Fenologica

Executive Summary

Fenologica is a San Francisco-based early-stage company founded in 2019 that leverages cloud computing, advanced data science, and big biology to unlock novel insights from functional genomics and synthetic biology. Its platform aims to deliver commercially unavailable information by integrating multi-omics data with machine learning, enabling researchers and biotech firms to accelerate discovery and development in areas such as gene therapy, metabolic engineering, and precision diagnostics. By focusing on the intersection of digital health, AI, and diagnostics, Fenologica positions itself to address bottlenecks in biological data analysis and interpretation. Despite being in an early stage, Fenologica’s approach has significant potential to transform how functional genomics data is utilized, particularly for synthetic biology applications. The company’s technology could enable more efficient design-build-test cycles in cell engineering and improve target identification for therapeutic interventions. However, the company faces typical early-stage risks, including the need for funding, validation through partnerships, and regulatory clarity. If successful, Fenologica could emerge as a key enabler in the growing bioeconomy, serving pharmaceutical, agricultural, and industrial biotechnology sectors.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round Completion60% success
• TBDFirst Commercial Partnership with a Biopharma Company50% success
• TBDBeta Launch of Synthetic Biology Platform40% success